BRIDGEWATER, N.J., March 12, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the company will be participating in the upcoming Oppenheimer's 29th Annual Healthcare Conference in New York, New York.
Valeritas' management is scheduled to present on Tuesday, March 19, 2019 at 10:20 AM Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at: www.valeritas.com.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas' flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
Lynn Pieper Lewis or Greg Chodaczek
Knight Marketing Communications, Ltd.
Source: Valeritas, Inc.